MRD Eradication With Alemtuzumab Consolidation Improves OS, PFS in CLL

Share this content:
Eradication of minimal residual disease with alemtuzumab consolidation therapy after chemotherapy improves progression-free and overall survival.
Eradication of minimal residual disease with alemtuzumab consolidation therapy after chemotherapy improves progression-free and overall survival.

Among patients with chronic lymphocytic leukemia (CLL), eradication of minimal residual disease (MRD) with alemtuzumab consolidation therapy after chemotherapy improves progression-free and overall survival, according to findings published in the British Journal of Haematology.1

MRD status after treatment is associated with remission duration and survival among patients with CLL. Researchers evaluated the impact of post-chemotherapy alemtuzumab consolidation on outcomes among patients with persistent low levels of detectable disease despite achieving a complete or partial remission.

For the open-label, phase 2 CLL207 study (ClinicalTrials.gov Identifier: NCT00458523), investigators screened the blood of patients with CLL who had received induction chemotherapy for MRD 6 to 24 months after chemotherapy. Patients with MRD-positive disease received alemtuzumab subcutaneously 3 times per week for 6 weeks. Those who were MRD-negative or non-responders after a marrow assessment discontinued therapy, while MRD-positive patients with 1 + log reduction received 6 additional weeks of immunotherapy consolidation.

Eighty-three percent of patients achieved MRD eradication from blood and bone marrow at the end of consolidation, with 38% remaining MRD-negative in the blood 6 months later.

Among the 18 patients who were MRD-negative at 6 months, median time to MRD relapse was 46 months. Patients who were MRD-negative at baseline who investigators followed up with had a similar median time to relapse.

The 5-year progression-free survival rate was significantly higher for patients who were MRD-negative at 6 months compared with MRD-positive patients (78% vs 39%; P = .010). The 5-year overall survival rate was also significantly better among MRD-negative patients (89% vs 64%; P = .029).

RELATED: Nivolumab + Ibrutinib Active in Relapsed/Refractory CLL and Richter Transformation

Thirty-six percent of alemtuzumab-treated patients reported serious adverse events, of which 19 were a result of treatment. One death was related to alemtuzumab therapy.

Reference

  1. Varghese AM, Howard DR, Pocock C, et al. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. Br J Haematol. 2016 Dec 29. doi: 10.1111/bjh.14342 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters